Introduction In the real-world APPRECIATE study (NCT02740218), most patients with
psoriasis demonstrated notable improvements on disease severity measures and reported …

Background Psoriasis is a chronic inflammatory skin disease, which requires long‐term, safe
and effective treatment. Apremilast, a small‐molecule PDE 4 inhibitor, has been introduced …

Background Apremilast, an oral, small‐molecule phosphodiesterase 4 inhibitor, has
demonstrated efficacy in patients with moderate‐to‐severe psoriasis. Objective Evaluate …

Background Randomized, controlled trials demonstrated efficacy and safety of apremilast for
moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective Assess long-term …

Psoriasis is a chronic inflammatory skin disease, most commonly resulting in the occurrence
of red and silver scaly plaques. About 30% of psoriasis sufferers develop psoriatic arthritis …

Background Apremilast, a small-molecule inhibitor of phosphodiesterase 4, works
intracellularly to modulate proinflammatory and anti-inflammatory mediator production, and …

Background Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works
intracellularly to modulate pro-inflammatory and anti-inflammatory mediators. This phase II …

Objective: To evaluate the clinical and biological activity of apremilast in patients with severe
plaque-type psoriasis. Research design and methods: Apremilast, a phosphodiesterase‑4 …

Background Many patients with psoriasis are bothered by symptoms in highly visible, pruritic
areas, such as the scalp. Objective To evaluate the efficacy and safety of apremilast for …

Background Apremilast, a small molecule specific inhibitor of phosphodiesterase 4, works
intracellularly to modulate pro‐inflammatory and anti‐inflammatory mediator production …